Press

Women in Psychedelics Announces atai as Platinum Sponsors

Nov 4 • 3 min read

The Women in Psychedelics Network , a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, as a platinum sponsor of…

Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression

Nov 4 • 3 min read

Biomind Labs Inc. (NEO: BMND | OTC: BMNDF | FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce positive initial results from part I of its Phase II…

Beckley Psytech to Attend and Present at the Jefferies London Healthcare Conference – November 15-17, 2022

Nov 4 • 2 min read

Beckley Psytech Limited, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, Steve Wooding, Chief Scientific Officer and Michael Norris, Chief Financial Officer, will attend the Jefferies London Healthcare Conference, being held in London from 15th to 17th November 2022,…

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

Nov 4 • 7 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2022 and gave an update on recent progress across its business. “With the announcement of our pivotal Phase 3 COMP360 program design for treatment-resistant depression,…

Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

Nov 3 • 2 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce its participation in the following upcoming investor events: Jefferies London Healthcare Conference, November 15-17, 2022 Doug Drysdale, Cybin’s Chief Executive Officer, will present on November 15, 2022 at 8:00 a.m. GMT and host investor meetings. To listen…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441